The researchers tested two approaches to smoking cessation. 1,357 adult smokers who expressed a desire to quit were taken in for the survey. Under the study, the patients were assigned to receive a free supply of approved cessation aid.
Twenty-eight percent of participants used e-cigarettes within three months of their discharge. Post six months, close to ten percent who smoked e-cigarettes had successfully kicked their habit as compared to twenty-seven percent who did not try e-cigarettes.
The study also suggested that occasional use of e-cigarette might not always impact the chance of smoking cessation, according to lead author Dr Nancy Rigotti, a researcher at Harvard Medical School and director of the Tobacco Research and Treatment Center at Massachusetts General Hospital in Boston.
E-cigarettes are often promoted as a tool to quit smoking - but the evidence doesn't support this. PHAA continues to advocate for a precautionary approach to their regulation until there is more evidence proving their safety.https://t.co/TEypySfvp4#ecigarettes #publichealth— Pub Health Assoc Aus (@_PHAA_) March 23, 2018
She further added that" The study is consistent with the hypothesis that smokers need to use e-cigarettes regularly and daily and switch completely from cigarettes to e-cigarettes for them to have the greatest chance of help." the funding for the research was done by Pfizer, who is also the maker of smoking-cessation drug Chantix.
Majority of US tobacco companies are developing e-cigarettes. The device has a glowing tip along with a heating element which turns liquid nicotine and favour rings into vapour which is then inhaled by the users.
Earlier studies suggested that flavour rings and other ingredients in e-liquids in e-cigarettes are generally linked to serious breathing health issues.
The dilemma about the safety of the e-cigarettes still remains the same and has not been answered by the current study. For the study, 302 smokers with heart ailments were randomly given either varenicline(Chantix)or a placebo pill for a period of three months(four weeks).
A later year, as the test revealed 40 percent of the people who were given varenicline had quit smoking as compared with 29 percent under placebo pill.
According to the lead study author Sarah Windle of Jewish General Hospital in Montreal, "These patients are at high risk for recurrent cardiovascular events (e.g., heart attacks, unstable angina, and mortality) if they continue to smoke."
"Of the first-line treatments used for smoking cessation, which also include various forms of nicotine replacement therapy and the prescription medication bupropion, varenicline is the most effective," said Robert Reid of the University of Ottawa Heart Institute. Reid, the author of an accompanying editorial, has received fees from Pfizer, maker of varenicline, and Johnson and Johnson, maker of various nicotine replacement products.
One advantage of the drug is that it dulls the effect of nicotine in the brain, making cigarettes less pleasurable. Nicotine replacement therapies, or e-cigarettes containing nicotine, may help reduce withdrawal by delivering smaller amounts of nicotine than traditional cigarettes, Reid said by email.
"The vast majority of smokers have made multiple quit attempts, with and without assistance and generally have some idea about how they respond to the currently available treatments," Reid added. "There is strong evidence that using these treatments, combined with behavioral support, makes it significantly more likely that smokers will be able to achieve long-term abstinence from tobacco."
(With inputs from Reuters)